Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged.

Slides:



Advertisements
Similar presentations
1 Vaccines and Related Biological Products Advisory Committee Meeting November 18, 2009 Questions for the Committee Prevnar 13 Pneumococcal 13-valent Conjugate.
Advertisements

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
Area-level mortality and morbidity predict ‘abortion proportion’ in England and Wales Sandra Virgo, Rebecca Sear Evolution and Human Behavior DOI: /j.evolhumbehav
Early impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in Singapore children, 2005 through 2010  Koh Cheng Thoon, Chia Yin Chong,
Thyroid cancer burden in Central and South America
Thyroid cancer burden in Central and South America
Table 1. Baseline Characteristics of the 36,636 Study Subjects
Volume 83, Issue 1, Pages (July 2014)
Volume 38, Issue 6, Pages (December 2014)
* LABORATORY-BASED SURVEILLANCE OF S. PNEUMONIAE INVASIVE DISEASE (IPD) IN CHILDREN: SEROTYPE DISTRIBUTION AND ESTIMATION OF VACCINES COVERAGE B. V. M.
Volume 44, Pages S43-S52 (September 2016)
Vaccines for the elderly
The Lancet Public Health
Evolution of the incidence of hepatitis B virus infection and immunization rates in a large French cohort born between 1960 and 1994  C. Ramière, L. Roche,
Neonatal invasive fungal infection in England 2004–2010
The Health Economic Impact of Universal Infant Vaccination with the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine.
M. Inghammar, G. Engström, G. Kahlmeter, B. Ljungberg, C. -G
Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period  J. Liñares, C. Ardanuy, R. Pallares, A.
Human papilloma viruses and cancer in the post-vaccine era
Ann-Marie M. Schoos, MD, PhD, Jacob D
Cystic fibrosis mortality trends in France
Economic evaluation of vaccination: capturing the full benefits, with an application to human papillomavirus  T. Bärnighausen, D.E. Bloom, E.T. Cafiero,
S. Wagenpfeil, A. Neiss, K. Banz, P. Wutzler 
The State of Pneumococcal Disease Prevention
Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia 
Pneumococcal Disease Prevention in Children: Issues in the Era of PCVs
Prevalence and estimated incidence of Toxoplasma infection among pregnant women in Poland: a decreasing trend in the younger population  D. Nowakowska,
Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.
Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the.
Emergence of a serotype 1 Streptococcus pneumoniae lineage colonising healthy children in Portugal in the seven-valent conjugate vaccination era  S. Nunes,
Invasive group A, B, C and G streptococcal infections in Denmark 1999–2002: epidemiological and clinical aspects  K. Ekelund, P. Skinhøj, J. Madsen, H.B.
Assessment of Streptococcus pneumoniae pilus islet-1 prevalence in carried and transmitted isolates from mother–infant pairs on the Thailand–Burma border 
Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants:
Andrea L. DiCarlo, Rebecca Fuldner, Joseph Kaminski, Richard Hodes 
Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine  E. Calbo, Á. Díaz, E.
Emergence of a serotype 1 Streptococcus pneumoniae lineage colonising healthy children in Portugal in the seven-valent conjugate vaccination era  S. Nunes,
Epidemiology of Meningococcal disease in Scotland
Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23- valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients.
The role of vaccination in preventing pneumococcal disease in adults
Socioeconomic Patterning in the Incidence and Survival of Children and Young People Diagnosed with Malignant Melanoma in Northern England  Richard J.Q.
Rate of improvement of CF life expectancy exceeds that of general population— Observational death registration study  Matthew N. Hurley, Tricia M. McKeever,
Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach?  Stefanie Desmet, Jan Verhaegen, Marc Van Ranst,
Haemophilus influenzae serotype b conjugate vaccine failure in twelve countries with established national childhood immunization programmes  S. Ladhani,
Can we control all-cause meningococcal disease in Europe?
Comparison of clinical and environmental isolates of Legionella pneumophila obtained in the UK over 19 years  T.G. Harrison, N. Doshi, N.K. Fry, C.A.
Daniel M. Musher, MD  Mayo Clinic Proceedings 
Evolving epidemiology of invasive Haemophilus infections in the post-vaccination era: results from a long-term population-based study  M.R. Berndsen,
Changing demographics in patients with vascular disease
Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults*   P. Durando, S.N. Faust,
Enterovirus infections in England and Wales, 2000–2011: the impact of increased molecular diagnostics  S. Kadambari, A. Bukasa, I.O. Okike, R. Pebody,
Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort.
Streptococcus pneumoniae serotype 1 causing invasive disease among children in Barcelona over a 20-year period (1989–2008)  C. Esteva, L. Selva, M.F.
Respiratory viruses, such as 2009 H1N1 influenza virus, could trigger temporal trends in serotypes causing pneumococcal disease  C. Launes, J.-J. García-García,
Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study 
Volume 388, Issue 10061, Pages (December 2016)
The role of antimalarial treatment in the elimination of malaria
Changes in Streptococcus pneumoniae serotypes causing invasive disease with non- universal vaccination coverage of the seven-valent conjugate vaccine 
UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years  Richard Peto, Jillian Boreham, Mike Clarke, Christina Davies, Valerie Beral 
F. Schaumburg, B. Biallas, E. Ngoune Feugap, A. S. Alabi, B
Vaccines for the elderly
Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in.
Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational.
Clinical Microbiology and Infection
Listeriosis: a resurgent foodborne infection
Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in England and Wales: a modelling and cost-effectiveness.
Clinical Burden of Invasive Pneumococcal Disease in Selected Developing Countries  Namaitijiang Maimaiti, PhD, Zafar Ahmed, PhD, Zaleha Md Isa, PhD, Hasanain.
Familial phenotype differences in PKD11
Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study  Gayatri Amirthalingam,
Volume 349, Issue 9062, Pages (May 1997)
Male biological clock: a critical analysis of advanced paternal age
Presentation transcript:

Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and Wales  Abdelmajid Djennad, Mary E. Ramsay, Richard Pebody, Norman K. Fry, Carmen Sheppard, Shamez N. Ladhani, Nick J. Andrews  EClinicalMedicine  DOI: 10.1016/j.eclinm.2018.12.007 Copyright © 2018 Terms and Conditions

Fig. 1 Vaccine effectiveness by time since vaccination using the spline model and a linear decline. Individual estimates for each year are also shown but are based on small numbers within each year. EClinicalMedicine DOI: (10.1016/j.eclinm.2018.12.007) Copyright © 2018 Terms and Conditions

Fig. 2 Corrected trends in the elderly IPD incidence in England and Wales from 2000/01 to 2016/17. EClinicalMedicine DOI: (10.1016/j.eclinm.2018.12.007) Copyright © 2018 Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.